United Therapeutics (UTHR) Competitors $297.33 -0.83 (-0.28%) Closing price 04:00 PM EasternExtended Trading$297.51 +0.18 (+0.06%) As of 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock UTHR vs. ALNY, BIIB, INCY, NBIX, EXEL, BMRN, EXAS, RGEN, HALO, and IONSShould you be buying United Therapeutics stock or one of its competitors? The main competitors of United Therapeutics include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Incyte (INCY), Neurocrine Biosciences (NBIX), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Repligen (RGEN), Halozyme Therapeutics (HALO), and Ionis Pharmaceuticals (IONS). These companies are all part of the "biotechnology" industry. United Therapeutics vs. Its Competitors Alnylam Pharmaceuticals Biogen Incyte Neurocrine Biosciences Exelixis BioMarin Pharmaceutical Exact Sciences Repligen Halozyme Therapeutics Ionis Pharmaceuticals Alnylam Pharmaceuticals (NASDAQ:ALNY) and United Therapeutics (NASDAQ:UTHR) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends. Do analysts rate ALNY or UTHR? Alnylam Pharmaceuticals currently has a consensus target price of $346.13, suggesting a potential upside of 6.60%. United Therapeutics has a consensus target price of $383.08, suggesting a potential upside of 28.84%. Given United Therapeutics' higher probable upside, analysts clearly believe United Therapeutics is more favorable than Alnylam Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alnylam Pharmaceuticals 1 Sell rating(s) 3 Hold rating(s) 21 Buy rating(s) 0 Strong Buy rating(s) 2.80United Therapeutics 0 Sell rating(s) 4 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.69 Does the media favor ALNY or UTHR? In the previous week, Alnylam Pharmaceuticals had 16 more articles in the media than United Therapeutics. MarketBeat recorded 31 mentions for Alnylam Pharmaceuticals and 15 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 1.24 beat Alnylam Pharmaceuticals' score of 0.71 indicating that United Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 13 Very Positive mention(s) 3 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive United Therapeutics 10 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, ALNY or UTHR? Alnylam Pharmaceuticals has a beta of 0.23, suggesting that its stock price is 77% less volatile than the S&P 500. Comparatively, United Therapeutics has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Is ALNY or UTHR more profitable? United Therapeutics has a net margin of 40.44% compared to Alnylam Pharmaceuticals' net margin of -11.49%. United Therapeutics' return on equity of 19.33% beat Alnylam Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Alnylam Pharmaceuticals-11.49% -510.31% -6.48% United Therapeutics 40.44%19.33%16.73% Do institutionals and insiders hold more shares of ALNY or UTHR? 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 94.1% of United Therapeutics shares are held by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are held by insiders. Comparatively, 10.3% of United Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has preferable earnings & valuation, ALNY or UTHR? United Therapeutics has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlnylam Pharmaceuticals$2.25B18.83-$278.16M-$2.09-155.35United Therapeutics$2.88B4.66$1.20B$25.0611.86 SummaryUnited Therapeutics beats Alnylam Pharmaceuticals on 12 of the 16 factors compared between the two stocks. Get United Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding UTHR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UTHR vs. The Competition Export to ExcelMetricUnited TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.41B$2.44B$5.51B$9.40BDividend YieldN/A1.79%4.25%4.09%P/E Ratio11.869.1828.1319.87Price / Sales4.66470.33401.9788.80Price / Cash10.33160.6835.5357.53Price / Book2.064.738.265.72Net Income$1.20B$30.99M$3.24B$257.80M7 Day Performance-0.94%1.21%0.65%1.13%1 Month Performance3.64%10.30%8.13%11.37%1 Year Performance-10.29%-3.49%28.59%17.01% United Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UTHRUnited Therapeutics4.9873 of 5 stars$297.33-0.3%$383.08+28.8%-9.2%$13.41B$2.88B11.861,305Positive NewsInsider TradeALNYAlnylam Pharmaceuticals4.0274 of 5 stars$324.13-2.3%$341.91+5.5%+29.2%$42.26B$2.25B-155.092,230Trending NewsAnalyst ForecastAnalyst RevisionBIIBBiogen4.9034 of 5 stars$130.13-2.1%$188.48+44.8%-42.9%$19.07B$9.68B12.857,605Trending NewsInsider TradeAnalyst RevisionINCYIncyte4.622 of 5 stars$67.27-1.7%$74.53+10.8%+8.2%$13.02B$4.24B210.232,617Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionNBIXNeurocrine Biosciences4.4903 of 5 stars$127.88-1.0%$162.00+26.7%-9.5%$12.66B$2.36B43.351,800Trending NewsAnalyst RevisionEXELExelixis4.7739 of 5 stars$44.16-4.3%$43.56-1.4%+96.9%$12.04B$2.17B20.071,147Analyst ForecastBMRNBioMarin Pharmaceutical4.9888 of 5 stars$57.41-0.2%$93.61+63.1%-32.0%$11.01B$2.85B21.343,040News CoverageAnalyst ForecastEXASExact Sciences4.687 of 5 stars$52.48-1.6%$70.40+34.1%+8.1%$9.90B$2.76B-9.527,000Positive NewsRGENRepligen4.7155 of 5 stars$124.43-2.4%$172.83+38.9%-11.3%$6.99B$634.44M-276.511,778Positive NewsHALOHalozyme Therapeutics4.8481 of 5 stars$54.22+0.4%$61.90+14.2%+5.3%$6.68B$1.02B14.42390Positive NewsAnalyst ForecastIONSIonis Pharmaceuticals4.5464 of 5 stars$41.78-2.8%$58.25+39.4%-14.2%$6.65B$705M-13.971,069 Related Companies and Tools Related Companies ALNY Alternatives BIIB Alternatives INCY Alternatives NBIX Alternatives EXEL Alternatives BMRN Alternatives EXAS Alternatives RGEN Alternatives HALO Alternatives IONS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:UTHR) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding United Therapeutics Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share United Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free UTHR Stock Alerts